NASDAQ:NARI Inari Medical (NARI) Stock Price, News & Analysis $46.30 -0.69 (-1.47%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$45.86▼$47.2050-Day Range$37.11▼$47.9852-Week Range$36.73▼$71.85Volume1.11 million shsAverage Volume1.26 million shsMarket Capitalization$2.69 billionP/E RatioN/ADividend YieldN/APrice Target$65.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Inari Medical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside41.9% Upside$65.71 Price TargetShort InterestBearish7.59% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 21 Articles This WeekInsider TradingSelling Shares$3.84 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.41) to $0.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.21 out of 5 starsMedical Sector341st out of 929 stocksSurgical & Medical Instruments Industry52nd out of 99 stocks 4.4 Analyst's Opinion Consensus RatingInari Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageInari Medical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Inari Medical's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.59% of the outstanding shares of Inari Medical have been sold short.Short Interest Ratio / Days to CoverInari Medical has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inari Medical has recently increased by 11.36%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInari Medical does not currently pay a dividend.Dividend GrowthInari Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NARI. Previous Next 1.8 News and Social Media Coverage News SentimentInari Medical has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Inari Medical this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for NARI on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Inari Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inari Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,843,878.00 in company stock.Percentage Held by Insiders10.60% of the stock of Inari Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.98% of the stock of Inari Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inari Medical's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inari Medical are expected to grow in the coming year, from ($0.41) to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inari Medical is -112.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inari Medical is -112.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInari Medical has a P/B Ratio of 6.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Inari Medical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Inari Medical Stock (NASDAQ:NARI)Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Read More NARI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NARI Stock News HeadlinesMay 16 at 1:13 PM | insidertrades.comInari Medical, Inc. (NASDAQ:NARI) CFO Mitch C. Hill Sells 6,000 SharesMay 4, 2024 | insidertrades.comInsider Selling: Inari Medical, Inc. (NASDAQ:NARI) Director Sells $1,619,058.00 in StockApril 19, 2024 | insidertrades.comInari Medical, Inc. (NASDAQ:NARI) Director Sells $58,040.00 in StockApril 19, 2024 | insidertrades.comMitch C. Hill Sells 6,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) StockMay 16 at 6:39 PM | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Inari Medical, Inc. (NARI) InvestorsMay 16 at 4:52 PM | stockhouse.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Inari Medical, Inc. with Losses to Contact the FirmMay 16 at 4:23 PM | businesswire.comNASDAQ: NARI: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Inari Medical, Inc.May 16 at 1:59 PM | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Inari Medical, Inc. (NARI) InvestorsMay 16 at 12:07 PM | businesswire.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Inari Medical, Inc. (NARI) InvestorsMay 15 at 5:15 PM | stockhouse.comInari Medical, Inc. (NARI) Litigation Initiated After NARI Disclosed DOJ Probe of Business Practices - Hagens BermanMay 15 at 11:00 AM | prnewswire.comNARI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Inari Medical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 15 at 9:38 AM | finance.yahoo.comInari Medical (NARI) Fell on Investor ConcernsMay 15 at 6:14 AM | businesswire.comNARI INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Inari Medical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 14 at 11:38 PM | stockhouse.comLevi & Korsinsky Notifies Inari Medical, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NARIMay 14 at 11:38 PM | stockhouse.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Inari MedicalMay 14 at 9:37 PM | businesswire.comINARI MEDICAL SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Inari Medical, Inc. - NARIMay 14 at 6:04 PM | businesswire.comKirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Inari Medical, Inc. (NARI) InvestorsMay 14 at 3:25 PM | prnewswire.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Inari Medical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NARIMay 14 at 11:47 AM | businesswire.comROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Inari Medical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NARIMay 13, 2024 | businesswire.comGrant & Eisenhofer Files Class Action Lawsuit Against Inari Medical, Inc. on Behalf of Institutional InvestorMay 6, 2024 | globenewswire.comInari Medical to Participate in the 2024 Bank of America Securities Healthcare ConferenceMay 4, 2024 | finance.yahoo.comDirector William Hoffman Sells Shares of Inari Medical Inc (NARI)May 3, 2024 | finance.yahoo.comInari Medical, Inc. (NASDAQ:NARI) Just Reported, And Analysts Assigned A US$66.00 Price TargetMay 2, 2024 | finance.yahoo.comInari Medical, Inc. (NASDAQ:NARI) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comInari Medical First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsSee More Headlines Company Calendar Last Earnings2/28/2024Today5/16/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NARI CUSIPN/A CIK1531048 Webwww.inarimedical.com Phone877-923-4747FaxN/AEmployees1,300Year FoundedN/APrice Target and Rating Average Stock Price Target$65.71 High Stock Price Target$84.00 Low Stock Price Target$50.00 Potential Upside/Downside+41.9%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,640,000.00 Net Margins-4.54% Pretax Margin-2.04% Return on Equity-1.65% Return on Assets-1.23% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.19 Sales & Book Value Annual Sales$520.66 million Price / Sales5.17 Cash Flow$0.09 per share Price / Cash Flow516.93 Book Value$7.69 per share Price / Book6.02Miscellaneous Outstanding Shares58,138,000Free Float51,975,000Market Cap$2.69 billion OptionableOptionable Beta0.93 Key ExecutivesMr. Andrew J. Hykes (Age 51)CEO, President & Director Comp: $1.54MMr. Mitchell C. Hill (Age 65)Chief Financial Officer Comp: $864.63kDr. Thomas M. Tu M.D. (Age 51)Chief Medical Officer Comp: $865.63kMr. Paul A. Koehn (Age 61)Senior Vice President of Operations Mr. Kevin StrangeSenior Vice President of Finance, Accounting, Strategy & Business DevelopmentMr. John Hsu C.F.A.Vice President of Investor RelationsMs. Angela AhmadGeneral Counsel & SecretaryMr. Eric KhairySenior Vice President of MarketingMr. Tim BennerSenior VP of Sales & Senior VP of U.S. SalesMs. Tara DunnSenior VP & GM of LimFlowMore ExecutivesKey CompetitorsICU MedicalNASDAQ:ICUITandem Diabetes CareNASDAQ:TNDMiRhythm TechnologiesNASDAQ:IRTCNovoCureNASDAQ:NVCRNuVasiveNASDAQ:NUVAView All CompetitorsInsiders & InstitutionsiA Global Asset Management Inc.Bought 42,680 shares on 5/17/2024Ownership: 0.166%Motley Fool Asset Management LLCBought 21,582 shares on 5/17/2024Ownership: 0.113%Comerica BankSold 17,932 shares on 5/17/2024Ownership: 0.035%Jacobs Levy Equity Management Inc.Bought 298 shares on 5/16/2024Ownership: 0.444%California State Teachers Retirement SystemSold 2,782 shares on 5/16/2024Ownership: 0.089%View All Insider TransactionsView All Institutional Transactions NARI Stock Analysis - Frequently Asked Questions Should I buy or sell Inari Medical stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NARI shares. View NARI analyst ratings or view top-rated stocks. What is Inari Medical's stock price target for 2024? 7 analysts have issued 1-year price objectives for Inari Medical's shares. Their NARI share price targets range from $50.00 to $84.00. On average, they expect the company's share price to reach $65.71 in the next twelve months. This suggests a possible upside of 41.9% from the stock's current price. View analysts price targets for NARI or view top-rated stocks among Wall Street analysts. How have NARI shares performed in 2024? Inari Medical's stock was trading at $64.92 at the beginning of the year. Since then, NARI shares have decreased by 28.7% and is now trading at $46.30. View the best growth stocks for 2024 here. When is Inari Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our NARI earnings forecast. How were Inari Medical's earnings last quarter? Inari Medical, Inc. (NASDAQ:NARI) issued its earnings results on Wednesday, February, 28th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.09. The firm had revenue of $132.10 million for the quarter, compared to the consensus estimate of $131.82 million. Inari Medical had a negative net margin of 4.54% and a negative trailing twelve-month return on equity of 1.65%. The company's quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.11) EPS. What ETFs hold Inari Medical's stock? ETFs with the largest weight of Inari Medical (NASDAQ:NARI) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Clough Select Equity ETF (CBSE), Tema Cardiovascular and Metabolics ETF (HRTS), Clough Long/Short Equity ETF (CBLS), Invesco S&P SmallCap Health Care ETF (PSCH) and SPDR S&P Health Care Equipment ETF (XHE).iShares U.S. Medical Devices ETF (IHI). What guidance has Inari Medical issued on next quarter's earnings? Inari Medical updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $592.5 million-$602.5 million, compared to the consensus revenue estimate of $588.4 million. What other stocks do shareholders of Inari Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY). When did Inari Medical IPO? Inari Medical (NARI) raised $110 million in an initial public offering on Friday, May 22nd 2020. The company issued 7,300,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers. Who are Inari Medical's major shareholders? Inari Medical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.63%), Bamco Inc. NY (1.34%), Brown Capital Management LLC (0.90%), Price T Rowe Associates Inc. MD (0.64%), Jennison Associates LLC (0.59%) and Principal Financial Group Inc. (0.53%). Insiders that own company stock include Andrew Hykes, Ansbert Gadicke, Donald B Milder, Mitch C Hill, Mitch C Hill, Stanley Tang, Thomas Tu and William Hoffman. View institutional ownership trends. How do I buy shares of Inari Medical? Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NARI) was last updated on 5/17/2024 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Brokerage Import from Robinhood Robinhood Brokerage Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Never Pay a Monthly Subscription Fee Again. Upgrade your MarketBeat All Access account to a lifetime subscription and lock-in these benefits for life: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Upgrade Your Account Here Questions? Have a Question? — Check out these how-to videos or send us a message: Send Message Please enter a message. Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageCustomize Your NewsletterView Current Brokerage RankingsCheck Out The Live News FeedReview Premium ReportsView The Idea Engine Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.